Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

354
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
354
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

273
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
273

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Warburg effect in Chinese hamster ovary cell culture with pyruvate dehydrogenase kinase inhibitors.

Biotechnology progress·2026
Same author

Osmolyte-Based Formulations for Enhanced Thermal Stability of mRNA Drug Substance: A Systematic Screening and Optimization Study.

Pharmaceutical research·2026
Same author

Structural Elucidation of Fc- and Fab-Associated <i>N</i>-Glycans in Cetuximab Using Protein A-Assisted Domain-Resolved Glycan Profiling Using Mass Spectrometry.

Journal of the American Society for Mass Spectrometry·2026
Same author

Bioinformatic pipeline to identify potential therapeutic targets with subsequent isolation and characterization of novel human anti- DDR1 antibodies.

Scientific reports·2026
Same author

Rapid Identification of Counterfeit Biopharmaceuticals using Portable Fourier Transform Infrared Spectroscopy.

AAPS PharmSciTech·2026
Same author

A Multitechnique Spectroscopy Platform for Monitoring Heterogeneities in the Higher-Order Structure of mAb Therapeutics.

Molecular pharmaceutics·2026

Related Experiment Video

Updated: Apr 29, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

Establishing analytical comparability for "biosimilars": filgrastim as a case study.

Anurag S Rathore1, Rahul Bhambure

  • 1Department of Chemical Engineering, Indian Institute of Technology, Hauz Khas, New Delhi, 110016, India, asrathore@biotechcmz.com.

Analytical and Bioanalytical Chemistry
|May 29, 2014
PubMed
Summary

Biosimilar development requires establishing analytical comparability to the reference product. This study demonstrates using orthogonal analytical tools to confirm the quality, safety, and efficacy of biosimilars.

More Related Videos

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.8K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K

Related Experiment Videos

Last Updated: Apr 29, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.8K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K

Area of Science:

  • Biopharmaceutical development
  • Analytical chemistry
  • Regulatory science

Background:

  • The biopharmaceutical industry is increasingly focusing on biosimilar production due to upcoming patent expirations.
  • Biosimilars, complex protein-based therapeutics, require rigorous evaluation to ensure quality, safety, and efficacy comparable to originator products.
  • Establishing analytical comparability is a critical step in the regulatory approval process for biosimilars.

Purpose of the Study:

  • To present data from an analytical comparability exercise for biosimilar development.
  • To showcase the application of orthogonal analytical tools in demonstrating biosimilarity.
  • To provide a model approach for the development and commercialization of biosimilars.

Main Methods:

  • Utilized a panel of orthogonal analytical techniques to assess a model protein.
  • Selected Granulocyte Colony-Stimulating Factor (G-CSF/Filgrastim) expressed in Escherichia coli as the model biotherapeutic.
  • Focused on establishing analytical comparability between the biosimilar candidate and the reference product.

Main Results:

  • Demonstrated the successful application of multiple analytical methods to establish comparability.
  • Provided data supporting the comparable quality attributes of the biosimilar candidate.
  • The chosen analytical strategy effectively addressed the complexity of protein-based therapeutics.

Conclusions:

  • Analytical comparability is foundational for biosimilar approval.
  • Orthogonal analytical methods are essential for comprehensively characterizing biosimilars.
  • The presented approach offers a valuable framework for biosimilar development and regulatory submission.